ArticleBioinformatics (Oxford, England)2026
VirPLM: antigenic prediction of influenza A/H3N2 viruses with a fine-tuned protein language model.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
motivationHuman influenza A/H3N2 viruses undergo rapid antigenic evolution primarily driven by the hemagglutinin subunit 1 (HA1). Within HA1, amino acid substitutions under immune pressure cause antigenic drift, necessitating frequent updates to vaccine strains. While hemagglutination inhibition (HI) assays remain the gold standard for assessing antigenic relationships, their labor-intensive and low-throughput nature limits scalability. Fortunately, the rapid accumulation of HA1 sequences enables sequence-based antigenic prediction, yet effectively extracting informative representations from these viral sequences remains challenging.
resultsIn this study, we present VirPLM, a two-stage framework that adapts the ESM-2 protein language model to H3N2 HA1 sequences for antigenic prediction. VirPLM significantly outperforms representative methods and maintains robust performance under both cross-validation and retrospective time-split evaluations. Moreover, VirPLM identifies highly critical sites enriched in known regions related to antigenic evolution. In the season-specific coverage analysis, VirPLM-prioritized strains achieve higher estimated coverage rates than the corresponding historical strains recommended by the World Health Organization in most evaluated seasons, suggesting that VirPLM can provide complementary sequence-based evidence for candidate strain prioritization. AVAILABILITY AND IMPLEMENTATION: The source code is available at https://github.com/xingyili/VirPLM, and the version used in this study is archived in Zenodo (DOI: 10.5281/zenodo.21650323).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.